PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15947002-8 2005 SB203580 reduced photoaffinity labeling of GLUT4 by bio-LC-ATB-BMPA only in the insulin-stimulated state. SB 203580 0-8 insulin Homo sapiens 80-87 15947002-0 2005 Reduction of insulin-stimulated glucose uptake in L6 myotubes by the protein kinase inhibitor SB203580 is independent of p38MAPK activity. SB 203580 94-102 insulin Homo sapiens 13-20 15947002-2 2005 We previously showed that insulin activates p38MAPK, and inhibitors of p38MAPKalpha and p38MAPKbeta (e.g. SB203580) reduce insulin-stimulated glucose uptake without affecting GLUT4 translocation. SB 203580 106-114 insulin Homo sapiens 123-130 15947002-5 2005 SB203580 reduced insulin stimulation of glucose uptake in L6 myotubes overexpressing an SB203580-resistant p38alpha (drug-resistant p38alpha) but barely affected phosphorylation of the p38 substrate MAPK-activated protein kinase-2. SB 203580 0-8 insulin Homo sapiens 17-24 15928020-9 2005 In addition, SB-203580 also significantly prevented the enhancement of glucose uptake induced by AMPK and insulin (P < 0.05). SB 203580 13-22 insulin Homo sapiens 106-113 15947002-9 2005 Unless low levels of p38MAPK suffice to regulate glucose uptake, these results suggest that the inhibition of insulin-stimulated glucose transport by SB203580 is likely not mediated by p38MAPK. SB 203580 150-158 insulin Homo sapiens 110-117 15947002-10 2005 Instead, changes experienced by insulin-stimulated GLUT4 make it susceptible to inhibition by SB203580. SB 203580 94-102 insulin Homo sapiens 32-39 15665038-7 2005 These data suggest that SB203580 affects glucose turnover by the insulin-responsive GLUT4 transporter in 3T3-L1 adipocytes. SB 203580 24-32 insulin Homo sapiens 65-72 15155098-3 2003 RESULTS: High glucose, AGE, high insulin and H(2)O(2) could activate P38MAPK by oneself, and increased notably expression of phosphorylated-P38MAPK and P-selectin on cell line ECV304; Expression of P-selectin was inhibited significantly by SB203580. SB 203580 240-248 insulin Homo sapiens 33-40 15665038-0 2005 The p38 mitogen-activated protein kinase inhibitor SB203580 reduces glucose turnover by the glucose transporter-4 of 3T3-L1 adipocytes in the insulin-stimulated state. SB 203580 51-59 insulin Homo sapiens 142-149 15665038-3 2005 Consequently, treatment with the p38 MAPK inhibitor SB203580 reduces insulin-induced glucose uptake by approximately 30%. SB 203580 52-60 insulin Homo sapiens 69-76 15793256-8 2005 Preincubation of myotubes with the p38 MAPK inhibitor SB203580 reduced insulin- and PPARdelta-mediated increase in glucose uptake, whereas the mitogen-activated protein kinase kinase inhibitor PD98059 was without effect. SB 203580 54-62 insulin Homo sapiens 71-78 15228086-6 2004 The treatment of cells with p38 MAPK inhibitor, SB203580, blocked the insulin stimulated glucose uptake in sensitive as well as resistant cells and it also prevented the activation of p38 by insulin. SB 203580 48-56 insulin Homo sapiens 70-77 15228086-6 2004 The treatment of cells with p38 MAPK inhibitor, SB203580, blocked the insulin stimulated glucose uptake in sensitive as well as resistant cells and it also prevented the activation of p38 by insulin. SB 203580 48-56 insulin Homo sapiens 191-198 14511371-8 2003 Both arsenite and insulin-induced glucose uptake were inhibited partially by the p38 MAP kinase inhibitor, SB203580. SB 203580 107-115 insulin Homo sapiens 18-25 12637564-5 2003 Inhibition of p38 MAPK with SB203580 reduces insulin-stimulated glucose uptake without affecting GLUT4myc translocation. SB 203580 28-36 insulin Homo sapiens 45-52 12237252-14 2002 7 Treatment of cells with p38 inhibitor, SB203580, blocked insulin- and metformin-stimulated glucose uptake as well as p38 activation. SB 203580 41-49 insulin Homo sapiens 59-66 11574405-11 2001 Glucose- and insulin-stimulated translocation of PDX-1 to the nucleoplasm was inhibited by wortmannin and SB 203580, indicating that a pathway involving PI 3-kinase and SAPK2/p38 was involved; translocation was unaffected by PD 098959 and rapamycin, suggesting that neither mitogen-activated protein kinase nor p70(s6k) were involved. SB 203580 106-115 insulin Homo sapiens 13-20 11672439-1 2001 We previously reported that SB203580, an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), attenuates insulin-stimulated glucose uptake without altering GLUT4 translocation. SB 203580 28-36 insulin Homo sapiens 114-121 11672439-5 2001 This segregation of glucose uptake from GLUT4 translocation became more apparent when the two parameters were measured at 22 degrees C. Preincubation with the p38 MAPK inhibitors SB202190 and SB203580 reduced insulin-stimulated transport of either 2-deoxyglucose or 3-O-methylglucose by 40-60%. SB 203580 192-200 insulin Homo sapiens 209-216 11672439-6 2001 Pretreatment with SB203580 lowered the apparent transport V(max) of insulin-mediated 2-deoxyglucose and 3-O-methylglucose without any significant change in the apparent K(m) for either hexose. SB 203580 18-26 insulin Homo sapiens 68-75 11602680-8 2001 Thus, the p38 MAPK inhibitor SB203580 and SB202190 abolished insulin activation of NE transport yet failed to impact basal NET activity. SB 203580 29-37 insulin Homo sapiens 61-68 11443108-6 2001 To determine the signaling pathway involved in this TNF-alpha response to insulin, we pretreated the cells with three distinct protein kinase inhibitors: wortmannin, PD98059, and SB203580. SB 203580 179-187 insulin Homo sapiens 74-81 10464317-4 1999 Insulin-augmented (125)I-alpha(2)M* binding to macrophages was severely reduced by wortmannin, LY294002, PD98059, SB203580, or rapamycin. SB 203580 114-122 insulin Homo sapiens 0-7 10585868-8 1999 The effects of insulin were inhibited by the PtdIns 3-kinase inhibitors wortmannin and LY294002 and by the SAPK2 inhibitor SB203580, suggesting that its effects were mediated via activation of PtdIns 3-kinase and SAPK2. SB 203580 123-131 insulin Homo sapiens 15-22 10187787-10 1999 In conclusion, in the presence of SB203580, insulin caused normal translocation and cell surface membrane insertion of glucose transporters without stimulating glucose transport. SB 203580 34-42 insulin Homo sapiens 44-51 10187787-2 1999 Here we assessed the effect of SB203580, an inhibitor of the p38 MAP kinase family, on insulin-stimulated glucose transport in 3T3-L1 adipocytes and L6 myotubes. SB 203580 31-39 insulin Homo sapiens 87-94 8971075-7 1997 The reactivating kinase (RK, also known as p38 mitogen activated protein kinase) is induced by insulin, hydrogen peroxide, or sodium meta-arsenite in hepatoma cells, and these effects are blocked by SB203580, a selective inhibitor of RK. SB 203580 199-207 insulin Homo sapiens 95-102 10187787-3 1999 We found that SB203580, but not its inactive analogue (SB202474), prevented insulin-stimulated glucose transport in both cell types with an IC50 similar to that for inhibition of p38 MAP kinase (0.6 microM). SB 203580 14-22 insulin Homo sapiens 76-83 23564383-6 2013 Insulin-induced ACAT1 upregulation was blocked by the presence of PD98059 (an inhibitor of extracellular signal-regulated kinase, ERK) and SB203580 (an inhibitor of p38 mitogen-activated protein kinase, p38MAPK) but not by Wortmannin (an inhibitor of phosphatidylinositol 3-kinase, PI3K) or U73122 (an inhibitor of phospholipase C-gamma, PLCgamma). SB 203580 139-147 insulin Homo sapiens 0-7 33434144-11 2021 In contrast, inhibition of p38MAPK with SB203580 significantly reversed the nNOS-induced inhibition of insulin signaling activity (all P < 0.05). SB 203580 40-48 insulin Homo sapiens 103-110 21636835-6 2011 The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not. SB 203580 233-241 insulin Homo sapiens 103-110 21448845-11 2011 In insulin studies, PD98059 had no significant effect on progesterone synthesis while SB203580 abolished insulin-induced progesterone production. SB 203580 86-94 insulin Homo sapiens 105-112 18557764-10 2008 Addition of the p38 mitogen-activated protein kinase-inhibitor SB203580, which we have shown previously to enhance hESC cardiomyogenesis, to these insulin-free and serum-free conditions resulted in a cardiomyocyte content of >10% in differentiated cultures without any preselection. SB 203580 63-71 insulin Homo sapiens 147-154 17880767-6 2007 The p38 mitogen activated protein(MAP) kinase inhibitors SB203580 and SB202190, and partially the c-Jun NH2-terminal kinase (JNK) inhibitor SP600127, decreased insulin effect on VCAM-1. SB 203580 57-65 insulin Homo sapiens 160-167